When was Escient Pharmaceuticals founded?

Escient Pharmaceuticals was founded in 2017 and raised its 1st funding round 1 year after it was founded.

Where is Escient Pharmaceuticals located?

Escient Pharmaceuticals is headquartered in San Diego, United States. It is registered at 10578 Science Center Drive, Suite 250, San Diego, CA 92121.

How many employees does Escient Pharmaceuticals have?

As of Mar 01, 2026, the latest employee count at Escient Pharmaceuticals is 10 - 49.

Is Escient Pharmaceuticals a funded company?

Escient Pharmaceuticals is a funded company, having raised a total of $238M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on May 09, 2018.

When was the latest funding round of Escient Pharmaceuticals?

Escient Pharmaceuticals' latest funding was a $***** Series C round on Nov 28, 2022, with participation from 13 investors. Its primary sector is Immunology. In United States, the Immunology sector has seen $4.27B in funding in 2026 to date.

Where does Escient Pharmaceuticals rank among its competitors?

Escient Pharmaceuticals ranks 27th amongst 317 active competitors, of which 114 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Trimtech Therapeutics, which secured $14M in Jun, 2026.

Who are the top competitors of Escient Pharmaceuticals?

Escient Pharmaceuticals' top competitors include Upstream Bio, Odyssey and Septerna. Among them, Trimtech Therapeutics secured the most recent funding round in June, 2026.

Escient Pharmaceuticals - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of small molecule based therapeutics for the treatment of inflammatory diseases. It has developed the G protein-coupled receptor targeted drugs for the treatment of a broad range of neuro-immuno-inflammatory and autoreactive diseases.

Website: www.escientpharma.com
Email ID: *****@escientpharma.com
Phone Number: +1 **********
Registered Address: 10578 Science Center Drive, Suite 250, San Diego, CA 92121

Key Metrics

Founded Year

2017

Location

San Diego, United States

Stage

Acquired

Total Funding

$238M in 3 rounds

Latest Funding Round

Series C, Nov 28, 2022, $*****

Investors

5AM Ventures & 13 more

Ranked

27^th among 317 active competitors

Employee Count

10 - 49 as on Mar 01, 2026

Similar Companies

Upstream Bio & 379 more

Exit Details

Acquired by Incyte (Apr 23, 2024)

View Escient Pharmaceuticals' full profile

Escient Pharmaceuticals is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Escient Pharmaceuticals, Inc. CIN: 82-2065265 , United States, Active	Mar 29, 2017	-	44 (As on Dec 31, 2021)	-

Escient Pharmaceuticals got acquired by Incyte on Apr 23, 2024.

Click here to take a look at Escient Pharmaceuticals's acquisition in detail

Escient Pharmaceuticals has raised a total funding of $238M over 3 rounds. Its first funding round was on May 09, 2018. Its latest funding round was a Series C round on Nov 28, 2022 for $*****. 13 investors participated in its latest round. Escient Pharmaceuticals has 14 institutional investors.

Here is the list of recent funding rounds of Escient Pharmaceuticals:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 28, 2022	2348129	Series C	9055082	1661976	5057695	8858801
Sep 14, 2020	8541048	Series B	6128380	4834137	8712950	5983110
May 09, 2018	6358317	Series A	9734344	1570727	The Column Group & 2 more	6582334

Access funding benchmarks and valuations. Sign up today!

View details of Escient Pharmaceuticals's funding rounds and investors

The founders of Escient Pharmaceuticals is Marcus Boehm.

Here are the details of Escient Pharmaceuticals' key team members:

Marcus Boehm: Former Co-Founder of Escient Pharmaceuticals.

View details of Escient Pharmaceuticals's Founder profiles and Board Members

Escient Pharmaceuticals' employee count trend

Escient Pharmaceuticals has 10 - 49 employees as of Mar 26. Here is Escient Pharmaceuticals's employee count trend over the years:

Employee count trend for Escient Pharmaceuticals

Uncover Escient Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Escient Pharmaceuticals include Upstream Bio, Odyssey and Septerna. Here is the list of Top 10 competitors of Escient Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Upstream Bio 2021, Waltham (United States), Public	Developer of therapeutics for allergic and inflammatory diseases	$400M	Venrock, Enavate Sciences & 11 others	67/100
2nd	Odyssey 2018, Cambridge (United States), Public	Developer of immunotherapeutics for immunological and cancer diseases	$717M	Orbimed, Ascenta Capital & 29 others	66/100
3rd	Septerna 2020, San Bruno (United States), Public	Developer of GPCR drug discovery platform for multiple diseases	$250M	RA Capital Management, Third Rock Ventures ... & 14 others	66/100
4th	Ventyx Biosciences 2018, Encinitas (United States), Acquired	Developer of therapeutics to treat autoimmune diseases	$165M	VenBio, Logos Capital & 13 others	66/100
5th	Evommune 2020, Sacramento (United States), Public	Developer of therapeutic options for chronic inflammatory disorders	$276M	Pivotal bioVenture Partners, RA Capital Management ... & 18 others	66/100
6th	CalciMedica 2006, San Diego (United States), Public	Developer of CRAC channel inhibitor drugs for inflammatory diseases	$76.7M	Biogen, Valence Life Sciences & 11 others	64/100
7th	Vyome Therapeutics 2010, Princeton (United States), Public	Developer of therapeutics for the immuno-inflammatory conditions	$62.9M	Perceptive Advisors, Iron Pillar & 11 others	64/100
8th	Trimtech Therapeutics 2023, Cambridge (United Kingdom), Seed	They develop treatments for CNS and inflammatory disorders	$47M	Cambridge Innovation Capital, SV Health Investors ... & 11 others	61/100
9th	Emmaus Medical 2000, Torrance (United States), Acquired	Developer of small molecule therapeutics for the treatment of sickle cell anemia and sickle ß0-thalassemia	-	E&Investment, Mitsubishi UFJ Capital & 4 others	60/100
10th	Equillium 2017, San Diego (United States), Public	Developer of therapies for treating autoimmune and inflammatory disorders	-	ADAR1 Capital Management, Janus Henderson Investors ... & 6 others	60/100
27th	Escient Pharmaceuticals 2017, San Diego (United States), Acquired	Developer of small molecule based therapeutics for the treatment of inflammatory diseases	$238M	Perceptive Advisors, Redmile Group & 12 others	55/100